Title: Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and
clinical outcomes in patients with ulcerative colitis: a retrospective study
Version: 1 Date: 24 Feb 2023
Reviewer's report:
We read with interest of this study which aimed to explore the compositional changes of
T-lymphocyte subsets among UC patients and healthy controls and the correlation of T-
lymphocyte subsets and disease severity. But there are several issues need to be addressed.
1. The related topics has been published in Zhonghua Yi Xue Za Zhi. 2011 Jun 21;91(23):1605-8,
Gastroenterology 2005;128:1868-78, Clin Res Hepatol Gastroenterol 2017;41:693-702.,. Please
further clarify the  novelties in this work.
2. We hope to see whether there is predictive values of baseline T-lymphocyte subsets for
assessing treatment response of biologic agents of UC patients, such as Remicade, adalimumab,
or vedolizumab.
3. How healthy controls was defined was not clear? All received endoscopy assessments?
4. Is there any correlations between the T-lymphocyte subsets in blood and colon?
5. Instead of amounts of T-lymphocyte subsets, we focus on the function or activated status of
these cells, could you provide any data to further analysis?
6. Should consider other type of colitis as control.
Title: Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and
clinical outcomes in patients with ulcerative colitis: a retrospective study
Version: 1 Date: 24 Feb 2023
Reviewer's report:
We read with interest of this study which aimed to explore the compositional changes of
T-lymphocyte subsets among UC patients and healthy controls and the correlation of T-
lymphocyte subsets and disease severity. But there are several issues need to be addressed.
1. The related topics has been published in Zhonghua Yi Xue Za Zhi. 2011 Jun 21;91(23):1605-8,
Gastroenterology 2005;128:1868-78, Clin Res Hepatol Gastroenterol 2017;41:693-702.,. Please
further clarify the  novelties in this work.
2. We hope to see whether there is predictive values of baseline T-lymphocyte subsets for
assessing treatment response of biologic agents of UC patients, such as Remicade, adalimumab,
or vedolizumab.
3. How healthy controls was defined was not clear? All received endoscopy assessments?
4. Is there any correlations between the T-lymphocyte subsets in blood and colon?
5. Instead of amounts of T-lymphocyte subsets, we focus on the function or activated status of
these cells, could you provide any data to further analysis?
6. Should consider other type of colitis as control.
Please review this paper.
user
Title: Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and
clinical outcomes in patients with ulcerative colitis: a retrospective study
Version: 1 Date: 24 Feb 2023
Reviewer's report:
We read with interest of this study which aimed to explore the compositional changes of
T-lymphocyte subsets among UC patients and healthy controls and the correlation of T-
lymphocyte subsets and disease severity. But there are several issues need to be addressed.
1. The related topics has been published in Zhonghua Yi Xue Za Zhi. 2011 Jun 21;91(23):1605-8,
Gastroenterology 2005;128:1868-78, Clin Res Hepatol Gastroenterol 2017;41:693-702.,. Please
further clarify the  novelties in this work.
2. We hope to see whether there is predictive values of baseline T-lymphocyte subsets for
assessing treatment response of biologic agents of UC patients, such as Remicade, adalimumab,
or vedolizumab.
3. How healthy controls was defined was not clear? All received endoscopy assessments?
4. Is there any correlations between the T-lymphocyte subsets in blood and colon?
5. Instead of amounts of T-lymphocyte subsets, we focus on the function or activated status of
these cells, could you provide any data to further analysis?
6. Should consider other type of colitis as control.
assistant